Releases Details
Save the Date: Capital Markets Day
Released : May 29, 2019 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Save the Date: Capital Markets Day
Discussion topics will include MaxCyte's partner programmes and in-house oncology pipeline, and trends in the cell therapy industry. Demonstrations will also be given of the Company's new products. Light refreshments will be available after the presentations, with the opportunity for an informal Q&A with the MaxCyte management team.
Further details of the event will follow.
To register your interest or for more information, please contact Sarah Downing on 020 7886 2910 or via email at sarah.downing@panmure.com.
About MaxCyte
MaxCyte is a global clinical-stage cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based therapy to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered programme licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than
For further information, please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
|
+1 301 944 1660 |
Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns
|
+44 (0)20 7886 2500 |
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji |
+44 (0)203 709 5700 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the